Does the media prefer PFE or TEVA?

In the previous week, Pfizer had 10 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 33 mentions for Pfizer and 23 mentions for Teva Pharmaceutical Industries. Pfizer's average media sentiment score of 0.73 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 16 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or BMY?

In the previous week, Bristol Myers Squibb had 13 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 36 mentions for Bristol Myers Squibb and 23 mentions for Teva Pharmaceutical Industries. Bristol Myers Squibb's average media sentiment score of 0.86 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 15 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SNY or TEVA?

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Sanofi. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 8 mentions for Sanofi. Sanofi's average media sentiment score of 0.93 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GSK or TEVA?

In the previous week, GSK had 11 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 34 mentions for GSK and 23 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.70 beat GSK's score of 0.22 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 11 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 7 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 10 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TEVA or TAK?

Teva Pharmaceutical Industries currently has a consensus target price of $43.10, indicating a potential upside of 10.48%. Given Teva Pharmaceutical Industries' higher probable upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Teva Pharmaceutical Industries (TEVA) Competitors

$39.01 -0.24 (-0.61%)

As of 11:31 AM Eastern

Compare

TEVA vs. PFE, BMY, SNY, GSK, and TAK

Should you buy Teva Pharmaceutical Industries stock or one of its competitors? Teva Pharmaceutical Industries's main competitors and comparable companies include Pfizer (PFE), Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Teva Pharmaceutical Industries compare to Pfizer?

Pfizer (NYSE:PFE) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pfizer has a net margin of 6.80% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Pfizer currently has a consensus target price of $28.39, suggesting a potential upside of 3.10%. Teva Pharmaceutical Industries has a consensus target price of $43.10, suggesting a potential upside of 10.48%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

Pfizer has higher revenue and earnings than Teva Pharmaceutical Industries. Pfizer is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.51	$7.77B	$0.76	36.23
Teva Pharmaceutical Industries	$17.26B	2.63	$1.41B	$0.60	65.02

Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

In the previous week, Pfizer had 10 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 33 mentions for Pfizer and 23 mentions for Teva Pharmaceutical Industries. Pfizer's average media sentiment score of 0.73 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	16 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	10 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pfizer beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Teva Pharmaceutical Industries (NYSE:TEVA) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Bristol Myers Squibb has higher revenue and earnings than Teva Pharmaceutical Industries. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.63	$1.41B	$0.60	65.02
Bristol Myers Squibb	$48.19B	2.71	$7.05B	$4.54	14.09

Teva Pharmaceutical Industries currently has a consensus price target of $43.10, indicating a potential upside of 10.48%. Bristol Myers Squibb has a consensus price target of $66.33, indicating a potential upside of 3.70%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Bristol Myers Squibb had 13 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 36 mentions for Bristol Myers Squibb and 23 mentions for Teva Pharmaceutical Industries. Bristol Myers Squibb's average media sentiment score of 0.86 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	10 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	15 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bristol Myers Squibb has a net margin of 18.87% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Bristol Myers Squibb's return on equity of 66.90% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Bristol Myers Squibb	18.87%	66.90%	14.74%

Teva Pharmaceutical Industries has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Summary

Bristol Myers Squibb beats Teva Pharmaceutical Industries on 12 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Sanofi?

Sanofi (NASDAQ:SNY) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Sanofi currently has a consensus price target of $49.50, indicating a potential upside of 15.74%. Teva Pharmaceutical Industries has a consensus price target of $43.10, indicating a potential upside of 10.48%. Given Sanofi's higher possible upside, research analysts plainly believe Sanofi is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$1.91	22.39
Teva Pharmaceutical Industries	$17.26B	2.63	$1.41B	$0.60	65.02

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Sanofi. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 8 mentions for Sanofi. Sanofi's average media sentiment score of 0.93 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	10 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sanofi has a net margin of 8.66% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Summary

Sanofi beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to GSK?

GSK (NYSE:GSK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

15.7% of GSK shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, GSK had 11 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 34 mentions for GSK and 23 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.70 beat GSK's score of 0.22 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	11 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	7 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	10 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

GSK presently has a consensus price target of $56.50, suggesting a potential upside of 12.51%. Teva Pharmaceutical Industries has a consensus price target of $43.10, suggesting a potential upside of 10.48%. Given GSK's higher possible upside, equities analysts plainly believe GSK is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.09
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91

GSK has higher revenue and earnings than Teva Pharmaceutical Industries. GSK is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.36	$7.54B	$3.20	15.69
Teva Pharmaceutical Industries	$17.26B	2.63	$1.41B	$0.60	65.02

GSK has a net margin of 14.56% compared to Teva Pharmaceutical Industries' net margin of 4.08%. GSK's return on equity of 43.23% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Summary

GSK beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Teva Pharmaceutical Industries (NYSE:TEVA) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.63	$1.41B	$0.60	65.02
Takeda Pharmaceutical	$28.32B	2.12	-$1.01B	$0.34	55.22

Teva Pharmaceutical Industries currently has a consensus target price of $43.10, indicating a potential upside of 10.48%. Given Teva Pharmaceutical Industries' higher probable upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Takeda Pharmaceutical's net margin of 3.80%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 6 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 0.70 beat Takeda Pharmaceutical's score of 0.32 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	10 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TEVA vs. The Competition

Export

Metric	Teva Pharmaceutical Industries	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$45.36B	$12.50B	$7.20B	$23.11B
Dividend Yield	N/A	2.63%	2.57%	3.58%
P/E Ratio	64.87	794.70	273.78	28.48
Price / Sales	2.63	947.89	700.09	20.16
Price / Cash	N/A	89.50	77.71	34.34
Price / Book	5.67	10.47	10.44	4.70
Net Income	$1.41B	$2.84B	$3.49B	$1.07B
7 Day Performance	5.80%	-1.40%	-0.29%	-1.38%
1 Month Performance	6.05%	0.93%	-0.07%	-4.20%
1 Year Performance	108.72%	4.13%	19.14%	9.12%

Teva Pharmaceutical Industries Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TEVA Teva Pharmaceutical Industries	3.591 of 5 stars	$39.01 -0.6%	$43.10 +10.5%	+107.2%	$45.36B	$17.26B	64.87	33,950
PFE Pfizer	2.9691 of 5 stars	$28.42 -0.1%	$28.28 -0.5%	+14.8%	$162.16B	$62.58B	37.40	75,000	Analyst Upgrade
BMY Bristol Myers Squibb	4.4527 of 5 stars	$66.85 +0.0%	$66.06 -1.2%	+37.4%	$136.49B	$48.19B	14.72	32,500	Analyst Forecast Analyst Revision
SNY Sanofi	3.7704 of 5 stars	$44.24 flat	$49.50 +11.9%	-9.1%	$107.26B	$49.35B	23.16	74,846
GSK GSK	4.1097 of 5 stars	$49.88 0.0%	$53.00 +6.3%	+24.1%	$100.91B	$43.07B	15.60	66,841	Trending News Dividend Cut Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TEVA) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Teva Pharmaceutical Industries (TEVA) Competitors

TEVA vs. PFE, BMY, SNY, GSK, and TAK

How does Teva Pharmaceutical Industries compare to Pfizer?

Summary

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Summary

How does Teva Pharmaceutical Industries compare to Sanofi?

Summary

How does Teva Pharmaceutical Industries compare to GSK?

Summary

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA vs. The Competition

Teva Pharmaceutical Industries Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teva Pharmaceutical Industries (TEVA) Competitors

TEVA vs. PFE, BMY, SNY, GSK, and TAK

How does Teva Pharmaceutical Industries compare to Pfizer?

Do institutionals and insiders have more ownership in PFE or TEVA?

Is PFE or TEVA more profitable?

Do analysts rate PFE or TEVA?

Which has stronger earnings & valuation, PFE or TEVA?

Which has more risk & volatility, PFE or TEVA?

Does the media prefer PFE or TEVA?

Summary

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Which has higher valuation & earnings, TEVA or BMY?

Do analysts recommend TEVA or BMY?

Does the media favor TEVA or BMY?

Do insiders & institutionals believe in TEVA or BMY?

Is TEVA or BMY more profitable?

Which has more volatility and risk, TEVA or BMY?

Summary

How does Teva Pharmaceutical Industries compare to Sanofi?

Do analysts recommend SNY or TEVA?

Which has higher earnings & valuation, SNY or TEVA?

Does the media prefer SNY or TEVA?

Which has more volatility & risk, SNY or TEVA?

Do institutionals & insiders have more ownership in SNY or TEVA?

Is SNY or TEVA more profitable?

Summary

How does Teva Pharmaceutical Industries compare to GSK?

Do insiders & institutionals have more ownership in GSK or TEVA?

Does the media refer more to GSK or TEVA?

Which has more volatility and risk, GSK or TEVA?

Do analysts rate GSK or TEVA?

Which has higher valuation & earnings, GSK or TEVA?

Is GSK or TEVA more profitable?

Summary

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Do insiders and institutionals have more ownership in TEVA or TAK?

Which has higher valuation & earnings, TEVA or TAK?

Do analysts rate TEVA or TAK?

Is TEVA or TAK more profitable?

Does the media favor TEVA or TAK?

Which has more risk and volatility, TEVA or TAK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA vs. The Competition

Teva Pharmaceutical Industries Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools